Literature DB >> 22723049

Peripheral arterial disease and chronic heart failure: a dangerous mix.

Sally C Inglis1, Adriana Hermis, Sajad Shehab, Phillip J Newton, Sara Lal, Patricia M Davidson.   

Abstract

Chronic heart failure (CHF) is associated with a high comorbidity burden, adverse impact on quality of life and high health care utilisation. Peripheral arterial disease (PAD) and CHF share many risk, pathophysiological and prognostic features, and each has been associated with increased morbidity and mortality. PAD often goes undetected, and yet in spite of the availability of screening tools, this is not commonly considered in CHF care. A review of the electronic databases Medline, CINAHL and Cochrane CENTRAL was undertaken using the MeSH terms peripheral arterial disease, peripheral vascular disease, intermittent claudication and heart failure to identify studies examining the prevalence and clinical outcomes of coexisting PAD in patients with CHF. Five studies were identified. There are limited data describing the impact of PAD on CHF outcomes. As PAD may contribute to decreased capacity to exercise and other self-care behaviours, identifying those at risk and providing appropriate therapy are important. Based on this review, patients who are smokers and those with diagnosed coronary heart disease and diabetes should be targeted for the screening of PAD.

Entities:  

Mesh:

Year:  2013        PMID: 22723049     DOI: 10.1007/s10741-012-9331-1

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  47 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease.

Authors:  S Marlene Grenon; Joel Gagnon; York Hsiang
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

Review 3.  Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management.

Authors:  Khalil Murad; Dalane W Kitzman
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).

Authors:  Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

5.  Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study.

Authors:  J F Price; P I Mowbray; A J Lee; A Rumley; G D Lowe; F G Fowkes
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

6.  Peripheral arterial disease detection, awareness, and treatment in primary care.

Authors:  A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

Review 7.  Medical treatment of peripheral arterial disease.

Authors:  Graeme J Hankey; Paul E Norman; John W Eikelboom
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

8.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

9.  The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys.

Authors:  G C Leng; F G Fowkes
Journal:  J Clin Epidemiol       Date:  1992-10       Impact factor: 6.437

10.  Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004.

Authors:  Yechiam Ostchega; Ryne Paulose-Ram; Charles F Dillon; Qiuping Gu; Jeffery P Hughes
Journal:  J Am Geriatr Soc       Date:  2007-04       Impact factor: 5.562

View more
  10 in total

Review 1.  Modulating the vascular response to limb ischemia: angiogenic and cell therapies.

Authors:  John P Cooke; Douglas W Losordo
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

2.  Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.

Authors:  Pratik B Sandesara; Muhammad Hammadah; Ayman Samman-Tahhan; Heval M Kelli; Wesley T O'Neal
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

3.  A New Clinically Applicable Measure of Functional Status in Patients With Heart Failure: The 60-Foot Walk Test.

Authors:  Kristie M Harris; David S Krantz; Willem J Kop; Joanne Marshall; Shawn W Robinson; Jennifer M Marshall; Stephen S Gottlieb
Journal:  JACC Heart Fail       Date:  2017-05-10       Impact factor: 12.035

4.  Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure.

Authors:  Joanne Simpson; Pardeep S Jhund; Lars H Lund; Sandosh Padmanabhan; Brian L Claggett; Li Shen; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Milton Packer; Jean L Rouleau; Guenther Mueller-Velten; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray
Journal:  JAMA Cardiol       Date:  2020-04-01       Impact factor: 14.676

Review 5.  Homocysteine lowering interventions for peripheral arterial disease and bypass grafts.

Authors:  Alina Andras; Gerard Stansby; Monica Hansrani
Journal:  Cochrane Database Syst Rev       Date:  2013-07-19

6.  The CHA2DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients.

Authors:  Akiomi Yoshihisa; Shunsuke Watanabe; Yuki Kanno; Mai Takiguchi; Akihiko Sato; Tetsuro Yokokawa; Shunsuke Miura; Takeshi Shimizu; Satoshi Abe; Takamasa Sato; Satoshi Suzuki; Masayoshi Oikawa; Nobuo Sakamoto; Takayoshi Yamaki; Koichi Sugimoto; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2016-07-18

7.  Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease.

Authors:  Birgitta Jönelid; Björn Kragsterman; Lars Berglund; Bertil Andrén; Nina Johnston; Bertil Lindahl; Jonas Oldgren; Christina Christersson
Journal:  JRSM Cardiovasc Dis       Date:  2019-04-16

8.  Peripheral artery disease and outcomes in patients with acute myocardial infarction.

Authors:  Rubina Attar; Axel Wester; Sasha Koul; Svend Eggert; Pontus Andell
Journal:  Open Heart       Date:  2019-05-12

9.  Mortality Risk Among Heart Failure Patients With Depression: A Nationwide Population-Based Cohort Study.

Authors:  Kasper Adelborg; Morten Schmidt; Jens Sundbøll; Lars Pedersen; Poul Videbech; Hans Erik Bøtker; Kenneth Egstrup; Henrik Toft Sørensen
Journal:  J Am Heart Assoc       Date:  2016-09-07       Impact factor: 5.501

10.  Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 - a nationwide study.

Authors:  Sadaf Kamil; Thomas S G Sehested; Nicholas Carlson; Kim Houlind; Jens F Lassen; Casper N Bang; Helena Dominguez; Christian T Pedersen; Gunnar H Gislason
Journal:  BMC Cardiovasc Disord       Date:  2019-10-24       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.